<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Congenital nephrotic syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Congenital nephrotic syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Congenital nephrotic syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term congenital nephrotic syndrome (CNS) refers to disease that is present at birth or within the first three months of life. Later onset, between three months and one year of age, is called infantile nephrotic syndrome. Most of these children have a genetic basis for the kidney disease and a poor outcome. The precise diagnosis of the glomerular lesion is based on clinical, laboratory, and histologic criteria.
        </p>
        <p>
         The causes of CNS will be discussed here.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of four reports indicate that variants in five different genes are responsible for more than 80 percent of CNS cases  (
         <a class="graphic graphic_table graphicRef80781" href="/z/d/graphic/80781.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         , which encodes nephrin (a key component of the podocyte slit diaphragm) and is responsible for the Finnish-type CNS. (See
         <a class="local">
          'Congenital Nephrotic Syndrome of Finnish type'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         , which encodes podocin (a protein that interacts with nephrin at the slit diaphragm) and is responsible for familial focal segmental glomerulosclerosis. (See
         <a class="local">
          'Congenital Nephrotic Syndrome and NPHS2 variants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610725&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7kscXiu13gi20PwR3Z8MfA&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS3
          </i>
         </a>
         (
         <em>
          PLCE1
         </em>
         ), which encodes phospholipase C epsilon (a signaling protein of many G protein-coupled receptors) and is responsible for early-onset nephrotic syndrome. (See
         <a class="local">
          'Diffuse mesangial sclerosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         , which encodes the transcription tumor suppressor (a protein involved in kidney and gonad development) and is responsible for Denys-Drash syndrome. (See
         <a class="local">
          'Diffuse mesangial sclerosis with Denys-Drash syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         , which encodes laminin beta 2 (a component of the glomerular basement membrane) and is responsible for Pierson syndrome with diffuse mesangial sclerosis [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Pierson syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         <em>
          NPHS2
         </em>
         and
         <em>
          NPHS1
         </em>
         are the most commonly affected genes, accounting for approximately 95 percent of cases [
         <a href="#rid2">
          2
         </a>
         ]. Genetic causes of CNS do not respond to glucocorticoid or immunosuppressive therapy.
        </p>
        <p>
         Nongenetic causes are often secondary and possibly curable disorders. These include infections, such as CNS induced by syphilis or toxoplasmosis, and immune disorders. (See
         <a class="local">
          'Infectious causes'
         </a>
         below and
         <a class="local">
          'Immune disorders'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CONGENITAL NEPHROTIC SYNDROME OF FINNISH TYPE
         </span>
         <span class="headingEndMark">
          —
         </span>
         CNS of the Finnish type (CNF;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F256300&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fma6R6Oq37jT7q%2FEVOfynfl&amp;TOPIC_ID=6137" target="_blank">
          MIM #256300
         </a>
         ) is most frequent in Finland, with initial studies suggesting an incidence of 1.2 per 10,000 births [
         <a href="#rid3">
          3,4
         </a>
         ]. With prenatal screening, the incidence has fallen to 0.9 per 10,000 births [
         <a href="#rid5">
          5
         </a>
         ]. CNF has also been described in various ethnic groups throughout the world [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         CNF is inherited as an autosomal recessive trait, with males and females being involved equally. There are no manifestations of the disease in heterozygous individuals.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Light microscopic studies of kidney biopsy specimens obtained early in the course of the disease show mild mesangial hypercellularity and increased mesangial matrix in the glomeruli [
         <a href="#rid6">
          6,9
         </a>
         ]. No immune deposits are detected by immunofluorescence studies. Over time, there is an increase in mesangial matrix accompanied by progressive glomerulosclerosis.
        </p>
        <p>
         Tubulointerstitial changes are also prominent in CNF. Irregular microcystic dilatation of proximal tubules is the most striking feature  (
         <a class="graphic graphic_picture graphicRef69624" href="/z/d/graphic/69624.html" rel="external">
          picture 1
         </a>
         ); however, this change is not specific and is not seen in all patients [
         <a href="#rid10">
          10
         </a>
         ]. Later in the course, interstitial fibrosis, lymphocytic and plasma cell infiltration, tubular atrophy, and periglomerular fibrosis develop in parallel with sclerosis of the glomeruli.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proteinuria in CNF results from an inherited error in the structure of the glomerular capillary filter. The abnormal gene
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         <em>
         </em>
         is localized to the long arm of chromosome 19 in both Finnish and non-Finnish families [
         <a href="#rid11">
          11-15
         </a>
         ] and encodes a transmembrane protein, named nephrin, which is a member of the immunoglobulin (Ig) family of cell adhesion molecules and is phosphorylated by Src family kinases [
         <a href="#rid16">
          16
         </a>
         ]. Nephrin is specifically located at the slit diaphragm of the glomerular podocytes; this could explain the absence of slit diaphragms and foot processes in patients with CNF who have a mutant nephrin protein [
         <a href="#rid17">
          17,18
         </a>
         ] and in mice with nephrin gene disruption [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         In the original report, four different variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         were found to segregate with the disorder in affected Finnish families [
         <a href="#rid14">
          14
         </a>
         ]. However, the two most common variants, Fin-major (nt121delCT) and Fin-minor (R1109X), account for nearly 90 percent of all affected Finnish patients and are associated with severe early onset of disease [
         <a href="#rid14">
          14,20,21
         </a>
         ].
        </p>
        <p>
         More than 200 variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         have been reported in non-Finnish CNF patients [
         <a href="#rid2">
          2,22-24
         </a>
         ]. Most of them are missense variants, many of them causing misfolding of the protein nephrin, which is retained in the endoplasmic reticulum [
         <a href="#rid25">
          25
         </a>
         ]. Some patients with certain variants have been reported to have a less severe form of the disease than Finnish patients [
         <a href="#rid22">
          22,26,27
         </a>
         ].
        </p>
        <p>
         A case report of two siblings with a milder form of CNF (ie, alternating periods of proteinuria and remission) showed that the two children were compound heterozygotes for two novel, nonconserved missense variants [
         <a href="#rid27">
          27
         </a>
         ]. Additional studies from kidney biopsy samples demonstrated expression of nephrin but with impaired function.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most infants with CNF are born prematurely (35 to 38 weeks), with a low birth weight for gestational age. The placenta is enlarged, being more than 25 percent of the total birth weight. Fetal distress is common, and the cranial sutures are widely separated due to delayed ossification. Infants often have a small nose and low ears. Flexion deformities of the hips, knees, and elbows are thought to be secondary to the large placenta.
        </p>
        <p>
         Edema is present at birth or appears during the first week of life in one-half of cases. Severe nephrotic syndrome with marked ascites is always present by three months. The proteinuria is highly selective early in the course of the disease, and hematuria is uncommon, reflecting the lack of inflammation in the glomeruli. The urinary protein losses are accompanied by profound hypoalbuminemia and severe hypogammaglobulinemia due, in part, to loss of selectivity as the disease progresses. As a result of these changes, nutritional status and statural growth are poor and affected infants are highly susceptible to bacterial infections (peritonitis, respiratory infections) and to thromboembolic complications due to the severity of the nephrotic syndrome. Hypothyroidism because of urinary losses of thyroxine-binding proteins is also common [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">
          "Hypercoagulability in nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
         The blood urea nitrogen and creatinine concentrations are initially normal. Kidney ultrasonography shows slightly enlarged, hyperechogenic kidneys without normal corticomedullary differentiation.
        </p>
        <p>
         End-stage kidney disease usually occurs between three and eight years of age. Several studies, however, have reported that some
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         variants are associated with end-stage kidney disease occurring after the age of 20 years [
         <a href="#rid20">
          20,26,29
         </a>
         ]. As an example, a case series from New Zealand reported that Maori children with CNS have prolonged kidney survival with medical therapy, including with
         <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">
          indomethacin
         </a>
         and an angiotensin-converting enzyme (ACE) inhibitor [
         <a href="#rid30">
          30
         </a>
         ]. Genetic evaluation detected a common founder variant, a missense variant at codon location 2131, in all of the affected Maori children.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nephrotic syndrome in CNF is always resistant to glucocorticoids and immunosuppressive drugs since it is not an immunologic disease. Furthermore, these drugs may be harmful due to the already high susceptibility to infection. A retrospective study of 21 infants with CNF, for example, found that 63 verified and 62 suspected septic episodes occurred over a mean follow-up period of one year [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Standard conservative treatment includes daily or every-other-day albumin infusion; gamma globulin replacement; nutrition with a high-protein, low-salt diet; vitamin and thyroxine substitution; and prevention of infections and thrombotic complications [
         <a href="#rid32">
          32
         </a>
         ]. Dietary intake is provided by tube feeding or parenteral alimentation [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         However, the rate of intercurrent complications remains high and growth and development are usually retarded. Several reported interventions to reduce protein excretion include unilateral nephrectomy [
         <a href="#rid34">
          34
         </a>
         ] and combination therapy of an ACE inhibitor and
         <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">
          indomethacin
         </a>
         , which lower intraglomerular pressure and lead to a fall in protein excretion [
         <a href="#rid35">
          35-37
         </a>
         ]. However, some patients may require bilateral nephrectomy in case of severe complications such as failure to thrive or thrombosis to prevent continued massive protein losses before the development of kidney failure [
         <a href="#rid34">
          34-36,38
         </a>
         ].
        </p>
        <p>
         If bilateral nephrectomy is performed, dialysis is provided until the patient reaches a weight of 8 to 9 kg. At this stage, kidney transplantation can be considered [
         <a href="#rid39">
          39,40
         </a>
         ]. The European Registry for Children on Renal Replacement Therapy reported excellent five-year patient (91 percent) and graft (89 percent) survival for both Finnish and non-Finnish NPHS1 patients that was comparable with patient and graft survival for children with CAKUT (congenital anomalies of the kidney and urinary tract) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Nephrotic syndrome can develop in the transplanted kidney. In one case series of 65 patients who received 77 kidney transplants, 23 episodes of recurrent nephrotic syndrome occurred in 13 patients with 19 grafts [
         <a href="#rid42">
          42
         </a>
         ]. All 13 affected patients had the Fin-major/Fin-major genotype, which is associated with the absence of nephrin. Eight (of 11 patients tested) had circulating antinephrin antibodies. Recurrence of disease is associated with graft loss. Plasma exchange combined with
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         and anti-CD20 antibodies has been successful in treating recurrence of nephrosis due to antinephrin antibodies [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Antenatal diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         CNF becomes manifest during early fetal life, beginning at the gestational age of 15 to 16 weeks. The initial symptom is fetal proteinuria, which leads to a more than 10-fold increase in the amniotic fluid alpha-fetoprotein (AFP) concentration. A parallel but less important increase in the maternal plasma AFP level is observed. These changes are not specific, but they may permit the antenatal diagnosis of CNF in high-risk families in which termination of the pregnancy might be considered [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         However, elevated AFP levels in maternal blood and amniotic fluid can also be observed before the 20
         <sup>
          th
         </sup>
         gestational week in pregnancies in which the fetus is a healthy carrier (heterozygote) of a pathogenic
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         variant. In one report, the AFP values for pregnancies in which the fetus was a healthy carrier overlapped with the elevated values in an affected fetus (homozygote) [
         <a href="#rid45">
          45
         </a>
         ]. Repeated measurement of AFP in amniotic fluid during the second trimester of pregnancy is needed to distinguish affected fetuses from carriers [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Genetic analyses diminish the risk of false-positive results in informative families [
         <a href="#rid47">
          47
         </a>
         ]. The four major haplotypes, which cover 90 percent of the CNF alleles in Finland, have been identified, resulting in a test with up to 95 percent accuracy. Commercial tests are also available to detect
         <em>
          NPHS1
         </em>
         variants. Antenatal diagnosis may be possible for a fetus following trophoblast biopsy if the responsible variants have been identified in an older sibling.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CONGENITAL NEPHROTIC SYNDROME AND
          <i>
           NPHS2
          </i>
          VARIANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         encodes an integral membrane protein, podocin, which is found exclusively in glomerular podocytes and is the causative gene for an autosomal recessive form of familial steroid-resistant nephrotic syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F256300&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fma6R6Oq37jT7q%2FEVOfynfl&amp;TOPIC_ID=6137" target="_blank">
          MIM #600995
         </a>
         ). A few patients with the typical clinical picture of CNS were found to lack
         <em>
          NPHS1
         </em>
         variants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study found homozygous
         <em>
          NPHS2
         </em>
         variants in two of five such patients [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         These findings were confirmed in a second report that described 11 patients with two recessive
         <em>
          NPHS2
         </em>
         variants who presented initially with CNS [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two additional cases with similar findings in terms of variants in
         <em>
          NPHS2
         </em>
         , but not
         <em>
          NPHS1
         </em>
         , were also reported in a study of 13 unrelated patients from Japan [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although affected individuals typically present in early childhood with proteinuria [
         <a href="#rid49">
          49
         </a>
         ], some have milder disease and present in adolescence or young adulthood. Issues related to treatment of nephrotic syndrome associated with
         <em>
          NPHS2
         </em>
         variants are discussed separately. Children develop end-stage kidney disease at a mean age of 6.6 years [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'NPHS2 gene'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Specific gene variants'
         </a>
         .)
        </p>
        <p>
         Associated features include cardiac anomalies [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Some patients also have both
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         variants, resulting in a triallelic abnormality (homozygous variants in one gene and a heterozygous variant in the other) [
         <a href="#rid26">
          26,29,51
         </a>
         ]. These findings demonstrate the genetic heterogeneity of CNS and the absence of clear genotype/phenotype correlations.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIFFUSE MESANGIAL SCLEROSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse mesangial sclerosis is another hereditary cause of CNS associated with glomerular injury and rapid progression to end-stage kidney disease. The same glomerular lesions are observed in Denys-Drash syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F194080&amp;token=tEpDslnpc0F0kICl%2Fz7sFQdsXnRDd5WxpnJNX2h2G8PS6XrqGp%2FLaLHCTl2%2Bx1IA&amp;TOPIC_ID=6137" target="_blank">
          MIM #194080
         </a>
         ), which is characterized by the combination of nephropathy, male pseudohermaphroditism, and Wilms tumor.
        </p>
        <p>
         Diffuse mesangial sclerosis is seen exclusively in infancy [
         <a href="#rid6">
          6,52-56
         </a>
         ] and appears to be transmitted in some families as an autosomal recessive trait [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The glomerular lesions are characterized in the early stages by a fibrillar increase in mesangial matrix without mesangial cell proliferation [
         <a href="#rid55">
          55-57
         </a>
         ]. The capillary walls are lined by hypertrophied podocytes  (
         <a class="graphic graphic_picture graphicRef77219" href="/z/d/graphic/77219.html" rel="external">
          picture 2
         </a>
         ). The fully developed lesion consists of the combination of thickening of the glomerular basement membranes and massive enlargement of mesangial areas, leading to reduction of the capillary lumens. The mesangial sclerosis eventually contracts the glomerular tuft into a sclerotic mass within a dilated urinary space  (
         <a class="graphic graphic_picture graphicRef56256" href="/z/d/graphic/56256.html" rel="external">
          picture 3
         </a>
         ). There is usually a corticomedullary gradient of involvement, with the deepest glomeruli being less affected. Tubules are severely damaged, especially in the deeper cortex, where they are markedly dilated and often contain hyaline casts.
        </p>
        <p>
         Electron microscopy reveals hypertrophic mesangial cells surrounded by an abundant mesangial matrix, which often contains collagen fibrils. The podocytes are hypertrophied and contain many vacuoles. There is also irregular effacement of foot processes with focal detachment of the epithelial cell from the glomerular basement membrane.
        </p>
        <p>
         Immunofluorescence shows mesangial deposits of IgM, C3, and C1q in the least affected glomeruli, while deposits of IgM and C3 outline the periphery of the sclerosed glomeruli. These immune deposits are probably nonspecific, occurring in areas of previous injury.
        </p>
        <p>
         The same glomerular lesion is observed in the Denys-Drash syndrome. As a result, all patients with diffuse mesangial sclerosis should be screened for the Denys-Drash syndrome. This consists of karyotyping in phenotypic females, looking for male pseudohermaphroditism with a 46 XY genotype, and ultrasonography in all patients, looking for Wilms tumor and abnormal gonadal development. Some investigators also suggest that an assessment for variants in the Wilms tumor predisposing gene,
         <em>
          WT1
         </em>
         , should be performed to help identify individuals at risk for the tumor [
         <a href="#rid58">
          58,59
         </a>
         ]. As an example, among 10 patients presenting with isolated diffuse mesangial sclerosis, four had variants in the
         <em>
          WT1
         </em>
         gene [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="local">
          'Diffuse mesangial sclerosis with Denys-Drash syndrome'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse mesangial sclerosis is associated with dominant pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         (23.1 percent) and biallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=6137" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         (17.8 percent),
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         <em>
         </em>
         (13.6 percent), and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         (4.9 percent) [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Abnormalities in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=6137" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         gene, which encodes phospholipase C epsilon, appear to cause isolated diffuse mesangial sclerosis. In one study of 12 children from six families with the disease, homozygous truncating gene variants in
         <em>
          PLCE1
         </em>
         were found in eight children [
         <a href="#rid1">
          1
         </a>
         ]. By comparison, missense variants found in two siblings were only associated with focal segmental glomerulosclerosis. A subsequent report involving a worldwide cohort of children with isolated diffuse mesangial sclerosis found truncating
         <em>
          PCLE1
         </em>
         variants in 10 of 35 families [
         <a href="#rid61">
          61
         </a>
         ].
         <em>
          WT1
         </em>
         variants were detected in three families.
        </p>
        <p>
         Phospholipase C epsilon is a member of the phospholipase family of enzymes that catalyzes the hydrolysis of polyphosphoinositides,w resulting in generation of second messengers (eg, inositol-1,4,5-triphosphate), which are involved in cell growth and differentiation. A pathogenetic role for
         <em>
          PLCE1
         </em>
         in glomerular development was supported by findings of disruption of the glomerular filtration barrier and edema in a
         <em>
          PLCE1
         </em>
         knockout zebrafish model.
        </p>
        <p>
         How a
         <em>
          PLCE1
         </em>
         gene defect results in changes in the glomerular nephrotic syndrome is unknown. One possible explanation is that phospholipase C epsilon interacts with GTPase-activating protein, which is known to interact with the slit diaphragm protein, nephrin. Perturbations of this normal interaction would have a downstream effect including the subsequent interaction of GTPase-activating protein with nephrin.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Clinical and laboratory features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newborns with diffuse mesangial sclerosis appear normal at birth, with a normal birth weight and without placental enlargement, in contrast with the low birth weight and enlarged placental seen in those with CNS of the Finnish type (CNF). The nephrotic syndrome may be present at birth or even suspected in utero by the finding of an elevated plasma alpha-fetoprotein (AFP) level in the mother or the discovery of large hyperechogenic kidneys [
         <a href="#rid62">
          62
         </a>
         ]. More commonly, however, proteinuria with a bland urine sediment develops postnatally, increasing progressively during the first or the second year of life. Various types of extrarenal signs have been reported in isolated patients including nystagmus, cataract, intellectual disability, microcephaly, severe myopia, and muscular dystrophy. (See
         <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">
          "Cataract in children"
         </a>
         .)
        </p>
        <p>
         All children progress to end-stage kidney disease, frequently in association with hypertension. This usually occurs before age three, within a few months after the discovery of kidney manifestations [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse mesangial sclerosis is reportedly resistant to corticosteroids and immunosuppressive drugs. In the previously mentioned report, however, there was a clinical response to
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         after failing initial steroid therapy in one of the eight children with diffuse mesangial sclerosis due to a genetic variant in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=6137" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. This case is the first reported cases of successful remission in patients with CNS due to genetic defect.
        </p>
        <p>
         The degree of proteinuria is typically less severe than in CNF, and specific supplemental therapy is usually not required.
        </p>
        <p>
         Treatment is supportive and consists of maintenance of electrolyte and water balance and adequate nutrition, prevention and treatment of infectious complications, and management of kidney failure. Bilateral nephrectomy has been considered at the time of transplantation in patients with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         variants because of the theoretical risk of developing a Wilms tumor. This issue remains unresolved, although some investigators have not found Wilms tumor in the kidneys from 14 children with kidney failure [
         <a href="#rid56">
          56
         </a>
         ]. Recurrent disease does not develop in the transplant.
        </p>
        <p>
         The combination of an angiotensin-converting enzyme (ACE) inhibitor and
         <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">
          indomethacin
         </a>
         therapy was used to treat one child with diffuse mesangial sclerosis [
         <a href="#rid38">
          38
         </a>
         ]. The child had a sustained clinical response and normal growth pattern and suffered no adverse effects.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIFFUSE MESANGIAL SCLEROSIS WITH DENYS-DRASH SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Denys-Drash syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F194080&amp;token=tEpDslnpc0F0kICl%2Fz7sFQdsXnRDd5WxpnJNX2h2G8PS6XrqGp%2FLaLHCTl2%2Bx1IA&amp;TOPIC_ID=6137" target="_blank">
          MIM #194080
         </a>
         ) refers to the triad of progressive kidney disease, male pseudohermaphroditism, and Wilms tumor [
         <a href="#rid63">
          63,64
         </a>
         ]. All of the patients were infants with heavy proteinuria progressing rapidly to kidney failure. Incomplete forms of the syndrome were described, and the glomerulopathy was identified as diffuse mesangial sclerosis [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Epidemiology and genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of cases of Denys-Drash syndrome have been reported [
         <a href="#rid63">
          63-67
         </a>
         ]. The Denys-Drash syndrome is usually sporadic, although occurrence in two kindreds has been reported. However, constitutional variants occur in the Wilms tumor predisposing gene,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Wilms tumor is an embryonic kidney tumor thought to arise from aberrant mesenchymal stem cell differentiation secondary to the loss of a tumor suppressor gene or genes [
         <a href="#rid69">
          69,70
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         gene lies at chromosomal position 11p13; it appears to encode a zinc finger protein, which is probably a transcription factor [
         <a href="#rid71">
          71-74
         </a>
         ].
         <em>
          WT1
         </em>
         is also expressed in the gonads, suggesting that the genital abnormalities in the Denys-Drash syndrome may result from pleiotropic effects of mutations in the
         <em>
          WT1
         </em>
         gene itself. This hypothesis was first confirmed in a report, which identified constitutional heterozygous variants within the
         <em>
          WT1
         </em>
         gene in some individuals with the Denys-Drash syndrome [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Subsequently, variants of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         have been found in most patients with this syndrome. Most abnormalities are missense changes either in exon 9, which encodes for zinc finger 3 (with a mutational hot spot at an arginine residue thought to interact with the consensus deoxyribonucleic acid [DNA] sequence), in exon 8, which encodes for zinc finger 2 or their intronic junctions [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse mesangial sclerosis is a constant feature of the Denys-Drash syndrome. It is associated with the two other components of the triad in the complete form but with only one of the two in the incomplete forms.
        </p>
        <p>
         The clinical course of the nephropathy is not different from that described above in isolated diffuse mesangial sclerosis. However, Wilms tumor may not be the first clinical manifestation of the syndrome. Thus, careful kidney ultrasonography should be performed every three months until the age of seven years, looking for nephroblastoma. The tumor may be unilateral or bilateral and is associated in a few cases with nodules of nephroblastomatosis [
         <a href="#rid57">
          57,68
         </a>
         ].
        </p>
        <p>
         Male pseudohermaphroditism, characterized by ambiguous genitalia or female phenotype with dysgenetic testis or streak gonads, is observed in all 46 XY patients. In contrast, all 46 XX children appeared to have a normal female phenotype, with normal ovaries, when the information was available. The finding of a normal male phenotype seems to exclude the diagnosis of Denys-Drash syndrome. (See
         <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">
          "Evaluation of the infant with atypical genital appearance (difference of sex development)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2889523390">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who reach end-stage kidney disease should undergo bilateral nephrectomy to prevent the development of Wilms tumor after kidney transplantation. Patients with a female phenotype and 46,XY karyotype should be considered for bilateral gonadectomy due to an increased risk of gonadoblastoma [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1672450046">
         <span class="h1">
          PIERSON SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pierson syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609049&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHaVDYEgGncusNCJ7EYrP37&amp;TOPIC_ID=6137" target="_blank">
          MIM #609049
         </a>
         ) is a rare autosomal recessive syndrome. Characteristic findings include CNS with histologic lesions of diffuse mesangial sclerosis, ocular malformations (microcoria, abnormal lens with cataracts, and retinal abnormalities), and neurologic symptoms (hypotonia, psychomotor retardation) [
         <a href="#rid78">
          78-80
         </a>
         ]. A majority of affected individuals progress to kidney failure within 12 months [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         This autosomal recessive disorder is due to variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         gene, which encodes laminin beta 2 [
         <a href="#rid81">
          81,82
         </a>
         ]. Laminin beta 2 is abundantly expressed in the glomerular basement membrane, where it plays a role in anchoring and in the development of podocyte foot processes [
         <a href="#rid83">
          83
         </a>
         ].
         <em>
          LAMB2
         </em>
         knockout mice exhibit CNS in association with anomalies of the retina and neuromuscular junction.
         <em>
          LAMB2
         </em>
         variants have also been found in patients with CNS and either no or less severe ocular abnormalities [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H217789269">
         <span class="h1">
          OTHER GENETIC CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other disorders with a genetic basis are rare causes of CNS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Galloway-Mowat syndrome
         </strong>
         – Galloway-Mowat syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F251300&amp;token=tEpDslnpc0F0kICl%2Fz7sFb7RHexADzCKuy2%2Bv61th%2Fl9cIUMPD4r9ezSmhgmbW2I&amp;TOPIC_ID=6137" target="_blank">
          MIM #251300
         </a>
         ) is characterized by microcephaly, intellectual disability, hiatus hernia, skeletal anomalies, and nephrotic syndrome [
         <a href="#rid85">
          85
         </a>
         ]. It appears to be transmitted as an autosomal recessive trait. The nephrotic syndrome presents early with a mean age of onset of three months and is usually severe and resistant to steroid therapy. Kidney biopsy reveals minimal changes or focal segmental glomerulosclerosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is genetic heterogeneity of the syndrome, as illustrated by the following case reports:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Loss-of-function variants of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616144&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4tPcytXfcdGyJD0p9vpK%2Fo&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WDR73
          </i>
         </a>
         gene have been reported in six families with Galloway-Mowat syndrome from two cohorts of unrelated patients [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recessive variants in the gene
         <em>
          s
         </em>
         encoding the four subunits of the KEOPS complex (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610107&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4%2FkmkRwCBjELdc%2FfE1NTUz&amp;TOPIC_ID=6137" target="_blank">
          <i>
           OSGEP
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608679&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaElxfpdiPG%2FH5ghx4lMjWk%2F&amp;TOPIC_ID=6137" target="_blank">
          <i>
           TP53RK
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608680&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaH6EPtjyN%2Fl%2FosaC%2BgR13cR&amp;TOPIC_ID=6137" target="_blank">
          <i>
           TPRKB
          </i>
         </a>
         , and
         <em>
         </em>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300060&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6HUp8nUfZGMZZUOU1E%2BPzNQ&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAGE3
          </i>
         </a>
         ) have also been identified in 37 affected individuals from 32 families [
         <a href="#rid88">
          88
         </a>
         ]. The
         <em>
          OSGEP
         </em>
         and
         <em>
          TP53RK
         </em>
         genes appear to encode proteins involved with the actin cytoskeleton and podocyte function.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A case report of four families with findings consistent with Galloway-Mowat syndrome identified a
         <em>
          NUP133
         </em>
         variant [
         <a href="#rid89">
          89
         </a>
         ].
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607613&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr7CtNAfB2DjByVWCgxINQt&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NUP133
          </i>
         </a>
         encodes nucleoporin, a subunit of the nuclear pore complex.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A case report of four families identified variants in the protein's zinc-finger domain of the transcriptional regulat
         <em>
          or
         </em>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617692&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6Meo3gpismh5Ph2yd4AkOX&amp;TOPIC_ID=6137" target="_blank">
          <i>
           PRDM15
          </i>
         </a>
         that resulted in nephrotic syndrome within the first two months of life, as well as brain anomalies, cardiac defects, and skeletal defects consistent with Galloway-Mowat syndrome [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Homozygous splice site variants in the gene
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605924&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp7b%2FfKEtsVHTMDtVVrTsjE&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WDR4
          </i>
         </a>
         that encodes a transfer ribonucleic acid-modifying enzyme was identified in three affected siblings of an Indian family with Galloway-Mowat syndrome [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mitochondrial disorders
         </strong>
         – An early-onset nephrotic syndrome has been reported in children with a coenzyme Q10 (ubiquinone) deficiency secondary to variants in genes involved in coenzyme Q10 biosynthesis (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609825&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHp%2B5KsecK5vQopUgERZe76&amp;TOPIC_ID=6137" target="_blank">
          <i>
           COQ2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610564&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5o4N5IKrrMIN5A17%2B0T50K&amp;TOPIC_ID=6137" target="_blank">
          <i>
           PDSS2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614647&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4ktyw1uLF7dy9lVKR2v5e2&amp;TOPIC_ID=6137" target="_blank">
          <i>
           COQ6
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615567&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7GRekhr9aoosDLB4C%2BxaR7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           COQ8B
          </i>
         </a>
         /
         <em>
          ADCK4
         </em>
         ) [
         <a href="#rid92">
          92-97
         </a>
         ]
         <em>
          .
         </em>
         Several associated symptoms suggest a mitochondrial disorder: hearing loss, nystagmus, encephalopathy, seizures, ataxia, hypotonia, developmental delay, diabetes mellitus, and elevated lactate levels. These patients may benefit from a treatment with ubiquinone (15 to 30 mg/kg per day) [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Herlitz junctional epidermolysis bullosa
         </strong>
         – This autosomal recessive disease is characterized by recurrent blister formation as a result of structural fragility within the skin. Variants of several genes involved in collagens, integrins, or laminins biosynthesis have been reported, some of them in association with a nephrotic syndrome and focal segmental glomerulosclerosis:
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F147557&amp;token=tEpDslnpc0F0kICl%2Fz7sFYR8Q1aXDxBReNYTLBTBwCSEMSRrIOlX%2BHGr3EWTZ%2BgR&amp;TOPIC_ID=6137" target="_blank">
          <i>
           ITGB4
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F192975&amp;token=tEpDslnpc0F0kICl%2Fz7sFQdsXnRDd5WxpnJNX2h2G8P5Luo0DRP5y5Q9cG2qbkIF&amp;TOPIC_ID=6137" target="_blank">
          <i>
           ITGA4
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605025&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrTqWvRa4Ze1cr3Zk6STbU8&amp;TOPIC_ID=6137" target="_blank">
          <i>
           ITGA3
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150310&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw%2FNwkdDEhXguOYXy%2Fqzk088&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAMB3
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602243&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqqYAUO7PXm1s9wgiCov%2Fpq&amp;TOPIC_ID=6137" target="_blank">
          <i>
           CD151
          </i>
         </a>
         [
         <a href="#rid99">
          99-101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nail-patella syndrome
         </strong>
         – Kidney disease varies among patients with nail-patella syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F161200&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313UhLVDoqgkjz4gtSZRAhVGW&amp;TOPIC_ID=6137" target="_blank">
          MIM #161200
         </a>
         ), an autosomal dominant disorder typically caused by variants of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602575&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqRycEx7BxoRhqcU3%2Fm%2FaqN&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LMX1B
          </i>
         </a>
         gene. Proteinuria may present at any age, and a few patients will develop nephrotic syndrome and progress to end-stage kidney disease. (See
         <a class="medical medical_review" href="/z/d/html/6116.html" rel="external">
          "Nail-patella syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         <strong>
          associations
         </strong>
         – CNS has been observed in case reports that have identified variants in the following genes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lowe syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F309000&amp;token=tEpDslnpc0F0kICl%2Fz7sFc1ZyERnYUPWku4Em4XflYznmDiqarhXl8DJnVqmWv%2By&amp;TOPIC_ID=6137" target="_blank">
          MIM #309000
         </a>
         ) – Two cases of CNS have been reported in patients with Lowe oculo-cerebro-renal syndrome, caused by variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300535&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6F5248%2B%2BROWTe%2Bj8YvKIOR7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           OCRL
          </i>
         </a>
         <em>
         </em>
         gene [
         <a href="#rid102">
          102
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7363.html" rel="external">
          "Dent disease (X-linked recessive nephrolithiasis)", section on 'Dent disease 2 versus Lowe syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sphingosine phosphate lyase insufficiency syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617575&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4iEzchyxCqSdaXuvA0kGo5&amp;TOPIC_ID=6137" target="_blank">
          MIM #617575
         </a>
         ) – Recessive variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603729&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyovrjNGyO5U9tLiT3558D1u&amp;TOPIC_ID=6137" target="_blank">
          <i>
           SGPL1
          </i>
         </a>
         <em>
         </em>
         gene have been reported to cause adrenal insufficiency with calcifications, ichthyosis, acanthosis, immunodeficiency, and CNS. Other symptoms include hypothyroidism, neurologic symptoms, and cryptorchidism [
         <a href="#rid103">
          103-106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nephrotic syndrome type 12 (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617609&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6HuxLRCwomE22JN2bfVfU0&amp;TOPIC_ID=6137" target="_blank">
          MIM #617609
         </a>
         ) – Variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606382&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyriYvcbQJ%2FbQQU29hD0An6g&amp;TOPIC_ID=6137" target="_blank">
          <i>
           MAGI2
          </i>
         </a>
         have been reported in patients with CNS [
         <a href="#rid107">
          107
         </a>
         ]. MAGI2 has been shown to interact with nephrin and regulate podocyte cytoskeleton and slit diaphragm dynamics.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital disorders of glycosylation – CNS has been reported in up to 20 percent of patients with congenital disorders of glycosylation [
         <a href="#rid108">
          108-110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112030.html" rel="external">
          "Overview of congenital disorders of glycosylation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biallelic
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609720&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE7Q5C%2B%2FrvQw24oY2fr6zkB&amp;TOPIC_ID=6137" target="_blank">
          <i>
           CRB2
          </i>
         </a>
         variants were described in five fetuses and one child from three families with severe neurologic involvement, including ventriculomegaly and kidney involvement, including elevated alpha-foetoprotein, and kidney histology showing tubular cysts at the corticomedullary junction and effacement of the podocyte foot processes [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CNS has been reported in single case reports of type I carbohydrate-deficient glycoprotein syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603147&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrzBITEDkwpc6qsR7316XKi&amp;TOPIC_ID=6137" target="_blank">
          MIM #603147
         </a>
         ) [
         <a href="#rid112">
          112
         </a>
         ] and a patient with a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601925&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoCBNrWLPFBQO9Tedh8xfnj&amp;TOPIC_ID=6137" target="_blank">
          <i>
           ARHGDIA
          </i>
         </a>
         gene variant [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1330637295">
         <span class="h1">
          NONGENETIC CAUSES
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Infectious causes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital syphilis – Congenital syphilis can cause membranous nephropathy [
         <a href="#rid114">
          114,115
         </a>
         ]. Histologic examination often shows a mixed pattern with membranous nephropathy and mesangial proliferation. Penicillin treatment leads to the resolution of the syphilis and kidney abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital toxoplasmosis – The nephrotic syndrome may be induced by congenital toxoplasmosis [
         <a href="#rid116">
          116
         </a>
         ]. Proteinuria may be present at birth or may develop during the first three months, in association with ocular or neurologic symptoms. Histologic examination often shows mesangial proliferation with or without focal segmental glomerulosclerosis. Treatment of toxoplasmosis or steroid therapy usually leads to remission of the proteinuria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital cytomegalovirus infection – CNS with diffuse mesangial sclerosis has been reported in association with cytomegalovirus [
         <a href="#rid117">
          117
         </a>
         ]. The patient responded to
         <a class="drug drug_pediatric" data-topicid="13331" href="/z/d/drug information/13331.html" rel="external">
          ganciclovir
         </a>
         therapy [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14430.html" rel="external">
          "Congenital cytomegalovirus infection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Immune disorders
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infantile systemic lupus erythematosus has been reported in a 10-week-old boy with CNS [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neonatal nephrotic syndrome due to membranous nephropathy has been diagnosed antenatally in infants with mothers who have variants in the metallomembrane endopeptidase gene, which encodes the podocyte protein neutral endopeptidase (NEP) [
         <a href="#rid120">
          120
         </a>
         ]. During pregnancy, the presence of fetal NEP protein induces a maternal alloimmune response. Maternal antibody to NEP fetal protein results in fetal podocyte injury, which may lead to chronic kidney failure. The mothers' IgG response to the expression of fetal NEP determines the severity of the neonatal disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Membranous nephropathy has also been reported in children under one year who had both circulating cationic bovine serum albumin (BSA) and anti-BSA antibodies [
         <a href="#rid121">
          121
         </a>
         ]. BSA was detected in the immune deposits, suggesting that the cationic BSA is pathogenic through binding to the anionic glomerular basement membrane and in situ formation of immune complexes. These observations raise the possibility that other food antigens might be involved in cases of membranous nephropathy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic testing is the first-choice diagnostic test because most cases of CNS are caused by genetic variants and fail to respond to immunosuppressive therapy. Screening for the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=6137" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         genes identifies underlying genetic anomalies in more than 80 percent of cases [
         <a href="#rid60">
          60,122
         </a>
         ]. Kidney biopsy results may be nonspecific and may not identify the underlying etiology, especially a genetic cause.
        </p>
        <p>
         Extrarenal manifestations can be helpful in the diagnosis, especially in syndromic cases. Neurologic examination, including brain imaging, may detect abnormal cerebral gyration or cerebellar atrophy suggestive of Galloway-Mowat syndrome, cerebellar and cerebral atrophy suggestive of CoQ10 deficiency, or ventriculomegaly in patients with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609720&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE7Q5C%2B%2FrvQw24oY2fr6zkB&amp;TOPIC_ID=6137" target="_blank">
          <i>
           CRB2
          </i>
         </a>
         variants [
         <a href="#rid122">
          122
         </a>
         ]. Genital abnormalities in an affected male infant suggest a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         variant and the diagnosis of Denys-Drash syndrome. Dysmorphic features or ophthalmologic anomalies suggest a genetic cause.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Nephrotic syndrome that presents at birth or within the first three months of life is defined as congenital nephrotic syndrome (CNS). Most children with CNS have a genetic basis for the kidney disease and a poor outcome. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – Variants of the following genes are responsible for the majority of cases of CNS:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         , which encodes nephrin (a key component of the podocyte slit diaphragm) and is responsible for the Finnish-type CNS. (See
         <a class="local">
          'Congenital Nephrotic Syndrome of Finnish type'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=6137" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         , which encodes podocin (a protein that interacts with nephrin at the slit diaphragm) and is responsible for familial steroid-resistant nephrotic syndrome. (See
         <a class="local">
          'Congenital Nephrotic Syndrome and NPHS2 variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=6137" target="_blank">
          <i>
           WT1
          </i>
         </a>
         , which encodes the transcription tumor suppressor (a protein involved in kidney and gonad development) and is responsible for Denys-Drash syndrome. (See
         <a class="local">
          'Diffuse mesangial sclerosis with Denys-Drash syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other etiologies of CNS include other less common genetic disorders and secondary causes such as infections (eg, syphilis or toxoplasmosis)  (
         <a class="graphic graphic_table graphicRef80781" href="/z/d/graphic/80781.html" rel="external">
          table 1
         </a>
         ) or immune disorders. (See
         <a class="local">
          'Other genetic causes'
         </a>
         above and
         <a class="local">
          'Nongenetic causes'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119:e907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HALLMAN N, HJELT L. Congenital nephrotic syndrome. J Pediatr 1959; 55:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallman N, Norio R, Rapola J. Congenital nephrotic syndrome. Nephron 1973; 11:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib R, Bois E. [Heterogeneity of early onset nephrotic syndromes in infants (nephrotic syndrome "in infants"). Anatomical, clinical and genetic study of 37 cases]. Helv Paediatr Acta 1973; 28:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan BS, Bureau MA, Drummond KN. The nephrotic syndrome in the first year of life: is a pathologic classification possible? J Pediatr 1974; 85:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibley RK, Mahan J, Mauer SM, Vernier RL. A clinicopathologic study of forty-eight infants with nephrotic syndrome. Kidney Int 1985; 27:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huttunen NP, Rapola J, Vilska J, Hallman N. Renal pathology in congenital nephrotic syndrome of Finnish type: a quantitative light microscopic study on 50 patients. Int J Pediatr Nephrol 1980; 1:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapola J, Sariola H, Ekblom P. Pathology of fetal congenital nephrosis: immunohistochemical and ultrastructural studies. Kidney Int 1984; 25:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kestilä M, Männikkö M, Holmberg C, et al. Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19. Am J Hum Genet 1994; 54:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenkkeri U, Männikkö M, McCready P, et al. Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999; 64:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage JM, Jefferson JA, Maxwell AP, et al. Improved prognosis for congenital nephrotic syndrome of the Finnish type in Irish families. Arch Dis Child 1999; 80:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollak MR. Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 2002; 13:3016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahdenperä J, Kilpeläinen P, Liu XL, et al. Clustering-induced tyrosine phosphorylation of nephrin by Src family kinases. Kidney Int 2003; 64:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruotsalainen V, Ljungberg P, Wartiovaara J, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A 1999; 96:7962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999; 10:2440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rantanen M, Palmén T, Pätäri A, et al. Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. J Am Soc Nephrol 2002; 13:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrakka J, Kestilä M, Wartiovaara J, et al. Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int 2000; 58:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol 2004; 19:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machuca E, Benoit G, Nevo F, et al. Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome. J Am Soc Nephrol 2010; 21:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cil O, Besbas N, Duzova A, et al. Genetic abnormalities and prognosis in patients with congenital and infantile nephrotic syndrome. Pediatr Nephrol 2015; 30:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoeb DS, Chernin G, Heeringa SF, et al. Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS). Nephrol Dial Transplant 2010; 25:2970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Doné SC, Khoshnoodi J, et al. Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet 2001; 10:2637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koziell A, Grech V, Hussain S, et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet 2002; 11:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitamura A, Tsukaguchi H, Hiramoto R, et al. A familial childhood-onset relapsing nephrotic syndrome. Kidney Int 2007; 71:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattoo TK. Hypothyroidism in infants with nephrotic syndrome. Pediatr Nephrol 1994; 8:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultheiss M, Ruf RG, Mucha BE, et al. No evidence for genotype/phenotype correlation in NPHS1 and NPHS2 mutations. Pediatr Nephrol 2004; 19:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong W, Morris MC, Kara T. Congenital nephrotic syndrome with prolonged renal survival without renal replacement therapy. Pediatr Nephrol 2013; 28:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ljungberg P, Holmberg C, Jalanko H. Infections in infants with congenital nephrosis of the Finnish type. Pediatr Nephrol 1997; 11:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobbie LJ, Lamb A, Eskell L, et al. Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. Pediatr Nephrol 2021; 36:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Schaefer F, Haffner D, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nat Rev Nephrol 2021; 17:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bérody S, Heidet L, Gribouval O, et al. Treatment and outcome of congenital nephrotic syndrome. Nephrol Dial Transplant 2019; 34:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomeranz A, Wolach B, Bernheim J, et al. Successful treatment of Finnish congenital nephrotic syndrome with captopril and indomethacin. J Pediatr 1995; 126:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufek S, Ylinen E, Trautmann A, et al. Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases. Pediatr Nephrol 2019; 34:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufek S, Holtta T, Trautmann A, et al. Management of children with congenital nephrotic syndrome: challenging treatment paradigms. Nephrol Dial Transplant 2019; 34:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heaton PA, Smales O, Wong W. Congenital nephrotic syndrome responsive to captopril and indometacin. Arch Dis Child 1999; 81:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahan JD, Mauer SM, Sibley RK, Vernier RL. Congenital nephrotic syndrome: evolution of medical management and results of renal transplantation. J Pediatr 1984; 105:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg C, Jalanko H, Koskimies O, et al. Renal transplantation in small children with congenital nephrotic syndrome of the Finnish type. Transplant Proc 1991; 23:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hölttä T, Bonthuis M, Van Stralen KJ, et al. Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016; 31:2317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuusniemi AM, Qvist E, Sun Y, et al. Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1). Transplantation 2007; 83:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmberg C, Jalanko H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr Nephrol 2014; 29:2309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryynänen M, Seppälä M, Kuusela P, et al. Antenatal screening for congenital nephrosis in Finland by maternal serum alpha-fetoprotein. Br J Obstet Gynaecol 1983; 90:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrakka J, Martin P, Salonen R, et al. Proteinuria and prenatal diagnosis of congenital nephrosis in fetal carriers of nephrin gene mutations. Lancet 2002; 359:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kestilä M, Järvelä I. Prenatal diagnosis of congenital nephrotic syndrome (CNF, NPHS1). Prenat Diagn 2003; 23:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Männikkö M, Kestilä M, Lenkkeri U, et al. Improved prenatal diagnosis of the congenital nephrotic syndrome of the Finnish type based on DNA analysis. Kidney Int 1997; 51:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sako M, Nakanishi K, Obana M, et al. Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome. Kidney Int 2005; 67:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol 2010; 25:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frishberg Y, Feinstein S, Rinat C, et al. The heart of children with steroid-resistant nephrotic syndrome: is it all podocin? J Am Soc Nephrol 2006; 17:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beale MG, Strayer DS, Kissane JM, Robson AM. Congenital glomerulosclerosis and nephrotic syndrome in two infants. Speculations and pathogenesis. Am J Dis Child 1979; 133:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumpelt HJ, Bachmann HJ. Infantile nephrotic syndrome with diffuse mesangial sclerosis: a disturbance of glomerular basement membrane development? Clin Nephrol 1980; 13:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kikuta Y, Yoshimura Y, Saito T, et al. Nephrotic syndrome with diffuse mesangial sclerosis in identical twins. J Pediatr 1983; 102:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbach J, Drukker A, Rosenmann E. Diffuse mesangial sclerosis--light, immunofluorescent and electronmicroscopy findings. Int J Pediatr Nephrol 1985; 6:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib R. Nephrotic syndrome in the 1st year of life. Pediatr Nephrol 1993; 7:347.
          </a>
         </li>
         <li class="breakAll">
          Habib R, Gubler MC, Antignac C, Gagnadoux MF. Diffuse mesangial sclerosis: A congenital glomerulopathy with nephrotic syndrome. In: Advances in Nephrology, Grunfeld JP (Ed), Year Book, Chicago 1993. p.43.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumacher V, Schärer K, Wühl E, et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int 1998; 53:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeanpierre C, Denamur E, Henry I, et al. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 1998; 62:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015; 26:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gbadegesin R, Hinkes BG, Hoskins BE, et al. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant 2008; 23:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spear GS, Steinhaus KA, Quddusi A. Diffuse mesangial sclerosis in a fetus. Clin Nephrol 1991; 36:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denys P, Malvaux P, Van Den Berghe H, et al. [Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism]. Arch Fr Pediatr 1967; 24:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drash A, Sherman F, Hartmann WH, Blizzard RM. A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. J Pediatr 1970; 76:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib R, Loirat C, Gubler MC, et al. The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion--report of 10 cases. Clin Nephrol 1985; 24:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallo GE, Chemes HE. The association of Wilms' tumor, male pseudohermaphroditism and diffuse glomerular disease (Drash syndrome): report of eight cases with clinical and morphologic findings and review of the literature. Pediatr Pathol 1987; 7:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadresic L, Leake J, Gordon I, et al. Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome). J Pediatr 1990; 117:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppes MJ, Campbell CE, Williams BR. The role of WT1 in Wilms tumorigenesis. FASEB J 1993; 7:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg RA. Tumor suppressor genes. Science 1991; 254:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huff V. Wilms tumor genetics. Am J Med Genet 1998; 79:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990; 61:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SB, Huang K, Palmer R, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999; 98:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelletier J, Bruening W, Li FP, et al. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991; 353:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997; 9:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipska BS, Ranchin B, Iatropoulos P, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney Int 2014; 85:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bredrup C, Matejas V, Barrow M, et al. Ophthalmological aspects of Pierson syndrome. Am J Ophthalmol 2008; 146:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matejas V, Hinkes B, Alkandari F, et al. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat 2010; 31:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki R, Sakakibara N, Ichikawa Y, et al. Systematic Review of Clinical Characteristics and Genotype-Phenotype Correlation in LAMB2-Associated Disease. Kidney Int Rep 2023; 8:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenker M, Tralau T, Lennert T, et al. Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: an autosomal recessive syndrome. Am J Med Genet A 2004; 130A:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VanDeVoorde R, Witte D, Kogan J, Goebel J. Pierson syndrome: a novel cause of congenital nephrotic syndrome. Pediatrics 2006; 118:e501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenker M, Aigner T, Wendler O, et al. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13:2625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasselbacher K, Wiggins RC, Matejas V, et al. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int 2006; 70:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnamurthy S, Rajesh NG, Ramesh A, Zenker M. Infantile nephrotic syndrome with microcephaly and global developmental delay: the Galloway Mowat Syndrome. Indian J Pediatr 2012; 79:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colin E, Huynh Cong E, Mollet G, et al. Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome. Am J Hum Genet 2014; 95:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosti RO, Dikoglu E, Zaki MS, et al. Extending the mutation spectrum for Galloway-Mowat syndrome to include homozygous missense mutations in the WDR73 gene. Am J Med Genet A 2016; 170A:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Rao J, Mollet G, et al. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nat Genet 2017; 49:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita A, Tsukaguchi H, Koshimizu E, et al. Homozygous splicing mutation in NUP133 causes Galloway-Mowat syndrome. Ann Neurol 2018; 84:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann N, Mzoughi S, Schneider R, et al. Mutations in PRDM15 Are a Novel Cause of Galloway-Mowat Syndrome. J Am Soc Nephrol 2021; 32:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Shril S, Sinha A, et al. Mutations in WDR4 as a new cause of Galloway-Mowat syndrome. Am J Med Genet A 2018; 176:2460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashraf S, Gee HY, Woerner S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013; 123:5179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007; 18:2773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 2011; 121:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng M, Falk MJ, Haase VH, et al. Primary coenzyme Q deficiency in Pdss2 mutant mice causes isolated renal disease. PLoS Genet 2008; 4:e1000061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scalais E, Chafai R, Van Coster R, et al. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). Eur J Paediatr Neurol 2013; 17:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iványi B, Rácz GZ, Gál P, et al. Diffuse mesangial sclerosis in a PDSS2 mutation-induced coenzyme Q10 deficiency. Pediatr Nephrol 2018; 33:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starr MC, Chang IJ, Finn LS, et al. COQ2 nephropathy: a treatable cause of nephrotic syndrome in children. Pediatr Nephrol 2018; 33:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hata D, Miyazaki M, Seto S, et al. Nephrotic syndrome and aberrant expression of laminin isoforms in glomerular basement membranes for an infant with Herlitz junctional epidermolysis bullosa. Pediatrics 2005; 116:e601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolaou N, Margadant C, Kevelam SH, et al. Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J Clin Invest 2012; 122:4375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalcin EG, He Y, Orhan D, et al. Crucial role of posttranslational modifications of integrin α3 in interstitial lung disease and nephrotic syndrome. Hum Mol Genet 2015; 24:3679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen KF, Steffensen GK. Congenital nephrotic syndrome associated with Lowe's syndrome. Child Nephrol Urol 1990; 10:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad R, Hadjidemetriou I, Maharaj A, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest 2017; 127:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest 2017; 127:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janecke AR, Xu R, Steichen-Gersdorf E, et al. Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications. Hum Mutat 2017; 38:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maharaj A, Theodorou D, Banerjee II, et al. A Sphingosine-1-Phosphate Lyase Mutation Associated With Congenital Nephrotic Syndrome and Multiple Endocrinopathy. Front Pediatr 2020; 8:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bierzynska A, Soderquest K, Dean P, et al. MAGI2 Mutations Cause Congenital Nephrotic Syndrome. J Am Soc Nephrol 2017; 28:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harshman LA, Ng BG, Freeze HH, et al. Congenital nephrotic syndrome in an infant with ALG1-congenital disorder of glycosylation. Pediatr Int 2016; 58:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morava E, Wosik H, Kárteszi J, et al. Congenital disorder of glycosylation type Ix: review of clinical spectrum and diagnostic steps. J Inherit Metab Dis 2008; 31:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranz C, Denecke J, Lehle L, et al. Congenital disorder of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase I. Am J Hum Genet 2004; 74:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavotinek A, Kaylor J, Pierce H, et al. CRB2 mutations produce a phenotype resembling congenital nephrosis, Finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein. Am J Hum Genet 2015; 96:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Knaap MS, Wevers RA, Monnens L, et al. Congenital nephrotic syndrome: a novel phenotype of type I carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis 1996; 19:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gee HY, Saisawat P, Ashraf S, et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013; 123:3243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan BS, Wiglesworth FW, Marks MI, Drummond KN. The glomerulopathy of congenital syphilis--an immune deposit disease. J Pediatr 1972; 81:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Losito A, Bucciarelli E, Massi-Benedetti F, Lato M. Membranous glomerulonephritis in congenital syphilis. Clin Nephrol 1979; 12:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahin B, Papadopoulou ZL, Jenis EH. Congenital nephrotic syndrome associated with congenital toxoplasmosis. J Pediatr 1974; 85:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besbas N, Bayrakci US, Kale G, et al. Cytomegalovirus-related congenital nephrotic syndrome with diffuse mesangial sclerosis. Pediatr Nephrol 2006; 21:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsuran D, Bhimma R, Ramdial PK, et al. The spectrum of HIV-related nephropathy in children. Pediatr Nephrol 2012; 27:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudley J, Fenton T, Unsworth J, et al. Systemic lupus erythematosus presenting as congenital nephrotic syndrome. Pediatr Nephrol 1996; 10:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipska-Ziętkiewicz BS, Ozaltin F, Hölttä T, et al. Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group. Eur J Hum Genet 2020; 28:1368.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6137 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17086182" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371932" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13673354" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4127143" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972657" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Estimating prevalence in single-gene kidney diseases progressing to renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4706144" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : [Heterogeneity of early onset nephrotic syndromes in infants (nephrotic syndrome "in infants"). Anatomical, clinical and genetic study of 37 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4371292" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The nephrotic syndrome in the first year of life: is a pathologic classification possible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3999542" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A clinicopathologic study of forty-eight infants with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7343522" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Renal pathology in congenital nephrotic syndrome of Finnish type: a quantitative light microscopic study on 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6384619" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pathology of fetal congenital nephrosis: immunohistochemical and ultrastructural studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8178817" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915943" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10208956" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Improved prognosis for congenital nephrotic syndrome of the Finnish type in Irish families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660941" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12444222" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12846735" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clustering-induced tyrosine phosphorylation of nephrin by Src family kinases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10393930" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nephrin is specifically located at the slit diaphragm of glomerular podocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10541305" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12039988" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972661" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503167" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Genetic forms of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20507940" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25720465" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Genetic abnormalities and prognosis in patients with congenital and infantile nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20172850" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11726550" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854170" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290294" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A familial childhood-onset relapsing nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7696098" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hypothyroidism in infants with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15338398" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : No evidence for genotype/phenotype correlation in NPHS1 and NPHS2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23949594" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Congenital nephrotic syndrome with prolonged renal survival without renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090651" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Infections in infants with congenital nephrosis of the Finnish type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33089377" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33514942" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29474669" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment and outcome of congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7815205" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Successful treatment of Finnish congenital nephrotic syndrome with captopril and indomethacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30374605" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30215773" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Management of children with congenital nephrotic syndrome: challenging treatment paradigms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10490532" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Congenital nephrotic syndrome responsive to captopril and indometacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6384451" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Congenital nephrotic syndrome: evolution of medical management and results of renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989242" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Renal transplantation in small children with congenital nephrotic syndrome of the Finnish type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27761660" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519780" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682440" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6189511" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antenatal screening for congenital nephrosis in Finland by maternal serum alpha-fetoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047969" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Proteinuria and prenatal diagnosis of congenital nephrosis in fetal carriers of nephrin gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673639" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prenatal diagnosis of congenital nephrotic syndrome (CNF, NPHS1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9067923" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Improved prenatal diagnosis of the congenital nephrotic syndrome of the Finnish type based on DNA analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15780077" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20333530" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291839" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The heart of children with steroid-resistant nephrotic syndrome: is it all podocin?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253708" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/463838" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Congenital glomerulosclerosis and nephrotic syndrome in two infants. Speculations and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7379364" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Infantile nephrotic syndrome with diffuse mesangial sclerosis: a disturbance of glomerular basement membrane development?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6682143" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Nephrotic syndrome with diffuse mesangial sclerosis in identical twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3897087" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diffuse mesangial sclerosis--light, immunofluorescent and electronmicroscopy findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8398639" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nephrotic syndrome in the 1st year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8398639" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Nephrotic syndrome in the 1st year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9607189" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9529364" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25349199" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18065803" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1889151" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Diffuse mesangial sclerosis in a fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4292870" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : [Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4316066" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3000666" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion--report of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2821524" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The association of Wilms' tumor, male pseudohermaphroditism and diffuse glomerular disease (Drash syndrome): report of eight cases with clinical and morphologic findings and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2172500" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8393819" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The role of WT1 in Wilms tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1659741" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Tumor suppressor genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781905" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Wilms tumor genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2154335" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2154702" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163761" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10490105" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1654525" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090524" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A clinical overview of WT1 gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24402088" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Genotype-phenotype associations in WT1 glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18672223" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Ophthalmological aspects of Pierson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20556798" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37705905" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Systematic Review of Clinical Characteristics and Genotype-Phenotype Correlation in LAMB2-Associated Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15372515" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: an autosomal recessive syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16864643" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pierson syndrome: a novel cause of congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367484" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912710" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22144119" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Infantile nephrotic syndrome with microcephaly and global developmental delay: the Galloway Mowat Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25466283" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Loss-of-function mutations in WDR73 are responsible for microcephaly and steroid-resistant nephrotic syndrome: Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27001912" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Extending the mutation spectrum for Galloway-Mowat syndrome to include homozygous missense mutations in the WDR73 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28805828" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30427554" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Homozygous splicing mutation in NUP133 causes Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33593823" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mutations in PRDM15 Are a Novel Cause of Galloway-Mowat Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30079490" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mutations in WDR4 as a new cause of Galloway-Mowat syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24270420" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855635" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21540551" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18437205" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Primary coenzyme Q deficiency in Pdss2 mutant mice causes isolated renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23816342" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29032433" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Diffuse mesangial sclerosis in a PDSS2 mutation-induced coenzyme Q10 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29637272" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : COQ2 nephropathy: a treatable cause of nephrotic syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16147969" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Nephrotic syndrome and aberrant expression of laminin isoforms in glomerular basement membranes for an infant with Herlitz junctional epidermolysis bullosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23114595" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Gain of glycosylation in integrinα3 causes lung disease and nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25810266" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Crucial role of posttranslational modifications of integrinα3 in interstitial lung disease and nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2253259" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Congenital nephrotic syndrome associated with Lowe's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28165343" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28165339" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28181337" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32322566" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : A Sphingosine-1-Phosphate Lyase Mutation Associated With Congenital Nephrotic Syndrome and Multiple Endocrinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27932480" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : MAGI2 Mutations Cause Congenital Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27325525" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Congenital nephrotic syndrome in an infant with ALG1-congenital disorder of glycosylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18500572" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Congenital disorder of glycosylation type Ix: review of clinical spectrum and diagnostic steps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14973782" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Congenital disorder of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25557780" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : CRB2 mutations produce a phenotype resembling congenital nephrosis, Finnish type, with cerebral ventriculomegaly and raised alpha-fetoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8982953" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Congenital nephrotic syndrome: a novel phenotype of type I carbohydrate-deficient glycoprotein syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23867502" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4566039" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The glomerulopathy of congenital syphilis--an immune deposit disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/383337" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Membranous glomerulonephritis in congenital syphilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4610418" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Congenital nephrotic syndrome associated with congenital toxoplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16523262" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Cytomegalovirus-related congenital nephrotic syndrome with diffuse mesangial sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22205506" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The spectrum of HIV-related nephropathy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971898" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Systemic lupus erythematosus presenting as congenital nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15464186" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21631322" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Early-childhood membranous nephropathy due to cationic bovine serum albumin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32467597" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
